These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21041907)

  • 21. [Individual therapy for the patients with YMDD mutation in HBV by lamivudine].
    Liu Z
    Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):558. PubMed ID: 14552722
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
    Pariente A; Tachet A; Poveda JD
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
    [No Abstract]   [Full Text] [Related]  

  • 23. [Chronic hepatitis-b-virus infections: new options for antiviral therapy].
    de Man RA; Honkoop P; Janssen HL; Schalm SW
    Ned Tijdschr Geneeskd; 1999 Sep; 143(37):1857-61. PubMed ID: 10526598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studying the treatment of chronic hepatitis B viral infection in special populations.
    Gish RG; Locarnini S
    Methods Mol Med; 2004; 96():465-98. PubMed ID: 14762288
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy effects of short-term lamivudine treatment on 22 hepatitis B patients with HBeAg-negative].
    Wu TS; Fang P
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):239. PubMed ID: 12716527
    [No Abstract]   [Full Text] [Related]  

  • 26. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 27. Do we need to determine viral genotype in treating chronic hepatitis B?
    Cooksley WG
    J Viral Hepat; 2010 Sep; 17(9):601-10. PubMed ID: 20529201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
    Yang DH; Xie YJ; Liang WF; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
    [No Abstract]   [Full Text] [Related]  

  • 29. [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Zoulim F
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S9-11. PubMed ID: 17075488
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of HBeAg negative chronic hepatitis B].
    Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
    [No Abstract]   [Full Text] [Related]  

  • 32. [Short-term therapeutic effect of lamivudine on patients with severe chronic hepatitis B].
    Lu HM; Yang YK; Han T; Zhang HZ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):500. PubMed ID: 12939189
    [No Abstract]   [Full Text] [Related]  

  • 33. [Lamivudine treatment consensus from relative experts in 2003].
    Lamivudine Clinical Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
    [No Abstract]   [Full Text] [Related]  

  • 34. Genotyping and genomic sequencing in clinical practice.
    Gish RG; Locarnini S
    Clin Liver Dis; 2007 Nov; 11(4):761-95, viii. PubMed ID: 17981228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Marcellin P; Lada O
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S5-8. PubMed ID: 17075487
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic hepatitis B: back to the future with HBsAg.
    Moucari R; Lada O; Marcellin P
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 38. [Analysis of HBV rtS213T mutation during interferon therapy].
    Ren WH; Zhao SL; Zhao ZJ; Li YQ; Tao HQ; Xiong H
    Zhonghua Gan Zang Bing Za Zhi; 2010 Mar; 18(3):227-8. PubMed ID: 20380803
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical consequences of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Cadranel JF
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S12-6. PubMed ID: 17075489
    [No Abstract]   [Full Text] [Related]  

  • 40. Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?
    Alberti A
    Hepatology; 2003 Jul; 38(1):18-20. PubMed ID: 12829981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.